Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0106213793
Thu, 24.03.2022
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, March 24, 2022Spexis provides business update and announces financial results for the full-year 2021
- Successful launch of Spexis AG as a reverse merger of Polyphor AG with EnBiotix Inc.
- Successful closing of a USD 12.8 million pre-merger financing
- First patient enrollment [ … ]
Wed, 09.03.2022
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, March 9, 2022Spexis to present strategy update and full-year 2021 financial results on March 24, 2022
Spexis AG (SIX: SPEX) announced today that it will publish its full-year financial results for 2021 on March 24 at 7.30am CET.
Jeffrey D. Wager, M.D. (CEO & Chairman) and Her [ … ]
Thu, 03.03.2022
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, March 03rd 2022Spexis achieves first CARB-X milestone for its thanatin derivatives program and receives funding of up to USD 1.9 million to initiate lead optimization
Spexis AG (SIX: SPEX) announced today that it has been awarded the second part of its phased funding grant from CA [ … ]
Thu, 30.12.2021
Polyphor AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, December 30, 2021
Polyphor closes merger with EnBiotix and is renamed Spexis
Polyphor AG (SIX: POLN) and EnBiotix Inc. today announced the closing of the merger of the two companies and the change of name of the combined company to Spexis AG. Pursuant to completion of the capital [ … ]
Wed, 29.12.2021
Polyphor AG
Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, December 29, 2021
Polyphor to inform about the financing of its merger partner EnBiotix
Polyphor AG (SIX: POLN) and EnBiotix Inc. today announced that EnBiotix has completed a convertible debenture raise of USD 11 million to finance its future operations. With this financing the l [ … ]
Wed, 15.12.2021
Polyphor AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, December 15, 2021
Polyphor and EnBiotix announce dosing of first patient in a first-in-human clinical trial of inhaled murepavadin
Polyphor AG (SIX: POLN) and EnBiotix Inc. today announced that the first subjects have been dosed in the first-in-human Phase I trial of a novel-cla [ … ]
Fri, 29.10.2021
Polyphor AG
Allschwil, Switzerland, October 29, 2021
Polyphor shareholders approve all resolutions for the planned merger with EnBiotix at the Extraordinary General Meeting
Polyphor AG (SIX: POLN) today announced that its shareholders approved all proposals of the Board of Directors at the Extraordinary General Meeting on October 28, 2021, with a significant [ … ]
Fri, 15.10.2021
Polyphor AG
Allschwil, Switzerland, October 15, 2021
Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer in connection with planned Enbiotix Merger
Polyphor AG (SIX: POLN) today announced that in connection with the proposed merger with EnBiotix, Inc. ("EnBiotix"), a request for confirmation regarding the absence of an oblig [ … ]
Mon, 27.09.2021
Polyphor AG
Allschwil, Switzerland, September 27, 2021
Polyphor publishes invitation to Extraordinary General Meeting and announces financial results for the first half 2021
- EGM on October 28, 2021 to be held to prepare merger with EnBiotix Inc, with shareholders not physically present, in accordance with COVID-19 ordinances.
- Pre-EGM information call [ … ]
Fri, 10.09.2021
Polyphor AG
Allschwil, Switzerland, September 10, 2021
Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by EnBiotix
Polyphor (SIX: POLN) and EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, today announced closing of the previously [ … ]